- Home
- CGEN vs INBX Comparison
CGEN vs INBX Comparison
Compare CGEN & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGEN
- INBX
- Stock Information
- Founded
- CGEN 1993
- INBX 2010
- Country
- CGEN Israel
- INBX United States
- Employees
- CGEN N/A
- INBX N/A
- Industry
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- CGEN Health Care
- INBX Health Care
- Exchange
- CGEN Nasdaq
- INBX Nasdaq
- Market Cap
- CGEN 167.4M
- INBX 178.5M
- IPO Year
- CGEN 2000
- INBX 2020
- Fundamental
- Price
- CGEN $1.73
- INBX $14.67
- Analyst Decision
- CGEN
- INBX Hold
- Analyst Count
- CGEN 0
- INBX 1
- Target Price
- CGEN N/A
- INBX N/A
- AVG Volume (30 Days)
- CGEN 265.3K
- INBX 82.4K
- Earning Date
- CGEN 08-05-2025
- INBX 08-12-2025
- Dividend Yield
- CGEN N/A
- INBX N/A
- EPS Growth
- CGEN N/A
- INBX N/A
- EPS
- CGEN N/A
- INBX 111.58
- Revenue
- CGEN $27,589,000.00
- INBX $200,000.00
- Revenue This Year
- CGEN N/A
- INBX N/A
- Revenue Next Year
- CGEN $173.80
- INBX N/A
- P/E Ratio
- CGEN N/A
- INBX $0.13
- Revenue Growth
- CGEN N/A
- INBX N/A
- 52 Week Low
- CGEN $1.13
- INBX $10.80
- 52 Week High
- CGEN $2.66
- INBX $17.79
- Technical
- Relative Strength Index (RSI)
- CGEN 57.84
- INBX 56.33
- Support Level
- CGEN $1.62
- INBX $14.34
- Resistance Level
- CGEN $1.81
- INBX $15.25
- Average True Range (ATR)
- CGEN 0.08
- INBX 0.82
- MACD
- CGEN -0.00
- INBX -0.09
- Stochastic Oscillator
- CGEN 65.22
- INBX 39.06
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.